- Product
- Only Paxlovid's prescription continues instead of Lagevrio
- by Jung, Heung-Jun Mar 29, 2022 05:54am
- Lagevrio, a Merck coronavirus PO treatment, has been supplied to pharmacies since the 26th, but has not yet been prescribed. According to pharmacies on the 28th, no code has been registered in the billing program. Pharmacy A in Seoul said, "In the case of clinics, prescriptions will only be possible if they are prescribed by hand," adding,
- Product
- Butterfly effect caused by brand name purchase
- by Kim JiEun Mar 23, 2022 05:50am
- From Rx drugs to OTC drugs, front-line pharmacies have recently had much time since the outbreak of COVID-19. Some say that pharmacy sales are also the biggest boom since the division of labor. Obviously, sales of generic drugs for certain diseases in most pharmacies have increased. However, pharmacists point out that there are concerns ab
- Product
- Paxlovid shortage to be resolved with Molnupiravir approval?
- by Jung, Heung-Jun Mar 21, 2022 05:55am
- The shortage of Paxlovid at pharmacies is expected to be partially resolved with the government's emergency approval of Merck (MDS)’s oral COVID-19 treatment ‘molnupiravir.’ On the 18th, the Central Disease Control Headquarters had announced that 88,276 courses of Paxlovid remain in stock in Korea. Also, with the grant of RAT(rapid ant
- Product
- Defective tablets of Lipitor were found
- by Kim JiEun Feb 8, 2022 05:54am
- Defective drugs have been found one after another in Lipitor, one of the most frequent prescription drugs, requiring caution when preparing. According to a pharmacist in Seoul on the 3rd, a defective tablet was recently found in a bottle of Lipitor again following November last year. The pharmacist said he found a suspicious substance wh
- Product
- Actinum is a troublemaker?
- by Kim JiEun Feb 7, 2022 05:57am
- Actinum is out of stock due to lack of inventory. The key is to return distribution inventory after the 11th. Multivitamin Actinum, which ambitiously entered Korea, is in a position to become a headache. It is not expected to be easy to order at pharmacies for the time being. According to an official at Dongwha Pharm on the 14th, Actinum'
- Product
- The gov is pushing to supply COVID-19 PO tx with pharmacies
- by Kang, Shin-Kook Jan 12, 2022 06:04am
- The government is taking full-fledged steps to supply COVID-19 PO treatment to pharmacies. The Central Disaster and Safety Counters Headquaters (CDSCHQ) will hold an online meeting this afternoon (10th) with drug organizations participating and discuss oral corona treatment prescriptions and dispensing. In other words, the direction of the CD
- Product
- Lee’s pledge to reimburse hair loss drug creates buzz
- by Jung, Heung-Jun Jan 6, 2022 06:09am
- The news that presidential candidate Lee Jae-Myung's is considering reimbursement of hair loss treatments as his election pledge is drawing attention for days. However, as many unresolved issues including creating empathy on its need, budgetary projections, and review of beneficiaries remain, it is unclear whether this may be practically
- Product
- Is the price of Paxlovid reasonable?
- by Jan 3, 2022 05:55am
- On the 27th, Paxlovid, an oral treatment for COVID-19, was approved for EUA by the MFDS, and the Pharmaceutical Association for Health Society asked questions about the insolvency and effectiveness of the screening process on the 30th. The Health Pharmaceutical Association said, "Paxlovid is expected to be used in patients with high risk amon
- Product
- Losartan's re-prescription & re-dispensing are imminent
- by Jung, Heung-Jun Dec 6, 2021 05:54am
- While the government's follow-up measures based on the results of Losartan impurity detection are expected to be announced this week, attention is being paid to the work guidelines for re-prescription and re-prevention. Items with problems with all manufacturing numbers are expected to be re-prescribed and re-manufactured, and items with prob
- Product
- Why Tagrisso and Opdivo failed reimbursement expansions
- by Moon, sung-ho Dec 6, 2021 05:53am
- The 3rd generation targeted therapy for lung cancer, ‘Tagrisso (osimertinib)’ once again failed to expand reimbursement to first-line treatment. The reason was that the drug was more appropriate as a second-line treatment in terms of cost-effectiveness. By failing to expand reimbursement at the last Cancer Drug Review Committee meeting held
